Stock analysts at Rodman & Renshaw started coverage on shares of Quantum Biopharma (NASDAQ:QNTM – Get Free Report) in a report released on Monday. The brokerage set a “buy” rating and a $8.00 price target on the stock. Rodman & Renshaw’s target price would indicate a potential upside of 159.74% from the company’s current price.
A number of other equities analysts have also issued reports on the stock. Weiss Ratings raised shares of Quantum Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 21st. Wall Street Zen raised shares of Quantum Biopharma from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.00.
Read Our Latest Stock Analysis on QNTM
Quantum Biopharma Stock Performance
Quantum Biopharma (NASDAQ:QNTM – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.06).
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in Quantum Biopharma in the 4th quarter worth approximately $76,000. Jane Street Group LLC purchased a new position in shares of Quantum Biopharma during the 4th quarter valued at approximately $80,000. Finally, Platform Technology Partners purchased a new position in shares of Quantum Biopharma during the 1st quarter valued at approximately $199,000. 1.24% of the stock is currently owned by hedge funds and other institutional investors.
Quantum Biopharma Company Profile
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.
See Also
- Five stocks we like better than Quantum Biopharma
- Palo Alto’s Rally Has One Big Problem Ahead of Earnings
- These 5 ETFs Have Raked in Cash This Year—What Do They All Have in Common?
- DLocal Is Testing the Breakout Level That Could Change Its Stock Story
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
